PRTO Proteon Therapeutics Inc.

0.49
-0.02  -3%
Previous Close 0.51
Open 0.5
Price To Book -8.17
Market Cap 9596863
Shares 19,585,394
Volume 873,062
Short Ratio
Av. Daily Volume 1,317,438

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

Phase 3 data released December 13, 2016 - primary endpoint not met.
Vonapanitase (PRT-201) PATENCY-1
Chronic kidney disease (CKD) patients undergoing surgical placement of an arteriovenous fistula (AVF)
Phase 3 data released Match 28, 2019 did not meet primary endpoint.
Vonapanitase (PRT-201) PATENCY-2
Chronic kidney disease (CKD) patients undergoing surgical placement of an arteriovenous fistula (AVF)
Phase 1 enrolment to be completed by the end of 2019.
Vonapanitase (PRT-201)
Peripheral artery disease (PAD)

Latest News

  1. The Daily Biotech Pulse: J&J Earnings, FDA Nod For Medicinova, Proteon To Explore Strategic Alternatives
  2. Proteon Therapeutics Announces Review of Potential Strategic Transactions
  3. Proteon Therapeutics Announces Top-Line Results From Phase 3 PATENCY-2 Clinical Trial of Vonapanitase in Radiocephalic Arteriovenous Fistulas
  4. Proteon Therapeutics: 4Q Earnings Snapshot
  5. Proteon Therapeutics Announces Fourth Quarter and Full-Year 2018 Financial Results
  6. Proteon Therapeutics to Present at the Cowen and Company 39th Annual Health Care Conference on March 11th
  7. 4 Healthcare Stocks Looking To Set February Highs
  8. Proteon Therapeutics Announces Publication of Results from Phase 3 PATENCY-1 Clinical Trial of Investigational Vonapanitase in Patients with Chronic Kidney Disease
  9. Does The Proteon Therapeutics, Inc. (NASDAQ:PRTO) Share Price Fall With The Market?
  10. New Research Coverage Highlights Yum! Brands, TELUS, Unifi, Proteon Therapeutics, Sabine Royalty Trust, and Algonquin Power & Utilities — Consolidated Revenues, Company Growth, and Expectations for 2018
  11. Proteon Therapeutics to Present at the Stifel 2018 Healthcare Conference November 13th
  12. Proteon Therapeutics Announces Third Quarter 2018 Financial Results
  13. Is Proteon Therapeutics Inc (NASDAQ:PRTO) A Strong Healthcare Bet?
  14. Proteon Therapeutics Inc’s (NASDAQ:PRTO) Earnings Dropped -27.47%, How Did It Fare Against The Industry?
  15. Blog Exposure - Proteon Extended Long-term Contract with Lonza for Commercial Supply of Vonapanitase's Active Pharmaceutical Ingredient